Results 171 to 180 of about 113,181 (243)

HBV treatment [PDF]

Hepatology, 2013
openaire   +1 more source

Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps. [PDF]

Vaccines (Basel)
Batbold E, Dashdorj N, Zoulim F, Bartosch B.   +3 more
europepmc   +1 more source

Re‐entry of donors deferred for false‐reactive screening tests in Canada: 10 years post implementation

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Canadian Blood Services implemented a re‐entry programme in 2014. Donors deferred because of false‐reactive or indeterminate screening tests can provide a specimen for re‐entry testing 6 months after their initial test, and resume donating if they test negative for all infectious markers.
Chinchin Wang, Steven J. Drews, Mark Bigham, Mindy Goldman, Sheila F. O'Brien   +4 more
wiley   +1 more source

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH). [PDF]

Liver Int
Săndulescu O, Şahin GÖ, Dudman SG, Said ZNA, Mondelli MU, ESCMID Study Group for Viral Hepatitis (ESGVH).   +5 more
europepmc   +1 more source

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

International Journal of Cancer, Volume 158, Issue 9, Page 2298-2308, 1 May 2026.
What's new? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar, Paula Lakrout, Valérie Potard, Aurélien Belot, Jacques Cadranel, Christine Jacomet, Christine Katlama, Esaïe Marshall, Olivier Lambotte, Romain Palich, Sylvie Ronot‐Bregigeon, Jean‐Philippe Spano, Anne‐Marie Bouvier, Alain Makinson, Dominique Costagliola   +14 more
wiley   +1 more source

A Community-Engaged Approach to Identifying and Addressing Viral Hepatitis Determinants in Michigan Asian American Communities. [PDF]

J Viral Hepat
Wongsirisakul P, Parikh ND, Troost J, Par H, Chowdhury T, Zhang Q, Wang YC, Wu TY, Perumalswami PV.   +8 more
europepmc   +1 more source

Infection Risk From Humans and Animals in the Anatomy Laboratory: A Scoping Review

Clinical Anatomy, Volume 39, Issue 3, Page 346-367, April 2026.
ABSTRACT Whole‐body dissection is a cornerstone of anatomy education. During and following the COVID‐19 pandemic, exposure to infectious agents and other risks of dissection were highlighted. To identify potential risks, one must have the data outlining these risks in specific situations.
Margaret A. McNulty, Elizabeth R. Agosto
wiley   +1 more source

Pre-Treatment HBV Activation Modulates Circulating Immune Markers in Hepatocellular Carcinoma Patients Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs. [PDF]

Cancer Manag Res
Qin L, Zhu L, Wang Y, Yang H, Shen J, Zhu X.   +5 more
europepmc   +1 more source

HBV-DNA [PDF]

, 2019
openaire   +1 more source

Treatment of Hepatocellular Carcinoma Using Endoscopic Ultrasound‐guided Radiofrequency Ablation: A Case Series

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Endoscopic ultrasound‐guided radiofrequency ablation (EUS‐RFA) is an emerging technique for treating pancreatic and neuroendocrine tumors in patients who are not candidates for surgery. However, there is limited evidence of EUS‐RFA in hepatic cancers.
Yogesh Harwani, Shreya Butala, Varun Shukla, Anand Patel, Surbhi Dogra Jani   +4 more
wiley   +1 more source